Stock Track | Everest Medicines Plummets 5% Intraday Following Annual Net Loss Report

Stock Track03-26

Everest Medicines' stock price fell sharply by 5.00% during intraday trading on Thursday. The decline occurred shortly after the company released its financial results for the fiscal year 2025.

The movement appears to be driven by investor reaction to the company's reported net loss of RMB 297.8 million for the year. Despite the company noting that its revenue rose to approximately CNY 1.71 billion and that the net loss had narrowed from the previous year, the persistence of a significant loss likely disappointed market participants.

Other details from the results included the strong commercial performance of Nefecon, which surpassed CNY 1.0 billion in sales in China following its inclusion in the national reimbursement drug list, and the recent approval for Velsipity in mainland China. However, the overriding focus for traders was the bottom-line loss, leading to the sell-off.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1151910655?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 11:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151910655","market":"sg","top_or_hot":-1,"title":"Stock Track | Everest Medicines Plummets 5% Intraday Following Annual Net Loss Report","media":"Stock Track","content":"<p>Everest Medicines' stock price fell sharply by 5.00% during intraday trading on Thursday. The decline occurred shortly after the company released its financial results for the fiscal year 2025.</p><p>The movement appears to be driven by investor reaction to the company's reported net loss of RMB 297.8 million for the year. Despite the company noting that its revenue rose to approximately CNY 1.71 billion and that the net loss had narrowed from the previous year, the persistence of a significant loss likely disappointed market participants.</p><p>Other details from the results included the strong commercial performance of Nefecon, which surpassed CNY 1.0 billion in sales in China following its inclusion in the national reimbursement drug list, and the recent approval for Velsipity in mainland China. However, the overriding focus for traders was the bottom-line loss, leading to the sell-off.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Everest Medicines Plummets 5% Intraday Following Annual Net Loss Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Everest Medicines Plummets 5% Intraday Following Annual Net Loss Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-26 11:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Everest Medicines' stock price fell sharply by 5.00% during intraday trading on Thursday. The decline occurred shortly after the company released its financial results for the fiscal year 2025.</p><p>The movement appears to be driven by investor reaction to the company's reported net loss of RMB 297.8 million for the year. Despite the company noting that its revenue rose to approximately CNY 1.71 billion and that the net loss had narrowed from the previous year, the persistence of a significant loss likely disappointed market participants.</p><p>Other details from the results included the strong commercial performance of Nefecon, which surpassed CNY 1.0 billion in sales in China following its inclusion in the national reimbursement drug list, and the recent approval for Velsipity in mainland China. However, the overriding focus for traders was the bottom-line loss, leading to the sell-off.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01952","symbol_name":"云顶新耀","start_time":0,"source_url":"","article_id":"1151910655","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151910655","pubTimestamp":1774494114,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Everest Medicines' stock price fell sharply by 5.00% during intraday trading on Thursday. The decline occurred shortly after the company released its financial results for the fiscal year 2025.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01952":"云顶新耀"},"translate_title":"个股追踪|珠峰医药公布年度净亏损后盘中暴跌5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":1},"content_text":"Everest Medicines' stock price fell sharply by 5.00% during intraday trading on Thursday. The decline occurred shortly after the company released its financial results for the fiscal year 2025.The movement appears to be driven by investor reaction to the company's reported net loss of RMB 297.8 million for the year. Despite the company noting that its revenue rose to approximately CNY 1.71 billion and that the net loss had narrowed from the previous year, the persistence of a significant loss likely disappointed market participants.Other details from the results included the strong commercial performance of Nefecon, which surpassed CNY 1.0 billion in sales in China following its inclusion in the national reimbursement drug list, and the recent approval for Velsipity in mainland China. However, the overriding focus for traders was the bottom-line loss, leading to the sell-off.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1151910655","isCrawlerRequest":true}